Top-News
Werbung

Attraktive Knock-Outs auf Biogen

Typ Hebel Bid / Ask WKN
Call
3,4 1,27 € / 1,28 €
SW3CYT
Typ Hebel Bid / Ask WKN
Den Basisprospekt sowie endgültige Bedingungen und Basisinformationsblätter erhalten Sie bei Klick auf das Dokument-Icon. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
Alle Knock-Outs auf Biogen
Pharmazeutika USA

Biogen News

Aktie
WKN:  789617 ISIN:  US09062X1037 US-Symbol:  BIIB
215,80 €
-1,90 €
-0,87%
19:51:08 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
145,30 Mio.
Marktkapitalisierung *
31,63 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
Nasdaq 100
IR-Website
zur Website
*Stand: 22.07.2023
Weiter abwärts? Short handeln - Jetzt mit Hebel 5,11: VX7HCZ

Biogen News

05:45 Uhr - PR Newswire
Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB
Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB PR Newswire
12.06.24 - PR Newswire
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit PR Newswire
11.06.24 - PR Newswire
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit PR Newswire
11.06.24 - wallstreet:online Zentralredaktion
Aktie nimmt Fahrt auf: Erfolg für Eli Lilly: Gremium empfiehlt Zulassung von Donanemab gegen Alzheimer!
Ein Expertengremium der US-​Arzneimittelbehörde FDA sprach sich am Montag einstimmig für die Zulassung von Eli Lillys Alzheimer-​Medikament Donanemab aus.Das Gremium ...
11.06.24 - wallstreet:online Zentralredaktion
Aktie nimmt Fahrt auf: Erfolg für Eli Lilly: FDA empfiehlt Zulassung von Donanemab gegen Alzheimer!
Experten der US-​Arzneimittelbehörde FDA sprachen sich am Montag einstimmig für die Zulassung von Eli Lillys Alzheimer-​Medikament Donanemab aus.Das Gremium betont, die ...
10.06.24 - PR Newswire
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit PR Newswire
10.06.24 - PR Newswire
Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm PR Newswire
10.06.24 - GlobeNewswire
FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
TOKYO and CAMBRIDGE, Mass., June 09, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate ...
09.06.24 - PR Newswire
FDA Accepts Eisai's Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
FDA Accepts Eisai's Filing of LEQEMBI® (lecanemab-​irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease ...
07.06.24 - PR Newswire
Biogen Inc. Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP
Biogen Inc. Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP PR Newswire
06.06.24 - PR Newswire
Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB
Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB PR Newswire
05.06.24 - PR Newswire
FINAL DEADLINE RAPIDLY APPROACHING: The Schall Law Firm Encourages Investors in Biogen Inc. with Losses to Contact the Firm
FINAL DEADLINE RAPIDLY APPROACHING: The Schall Law Firm Encourages Investors in Biogen Inc. with Losses to Contact the Firm PR Newswire
05.06.24 - PR Newswire
Investors who lost money on Biogen Inc. (BIIB) should contact The Gross Law Firm about pending Class Action - BIIB
Investors who lost money on Biogen Inc. (BIIB) should contact The Gross Law Firm about pending Class Action - BIIB PR Newswire
04.06.24 - PR Newswire
Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky
Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky PR Newswire
30.05.24 - GlobeNewswire
Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS
SOD1 -ALS is a devastating, uniformly fatal, and ultra-​rare genetic form of ALS estimated to affect less than 1,000 people in Europe 1 QALSODY is Biogen’s third rare disease ...
30.05.24 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB PR ...
30.05.24 - PR Newswire
BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! PR ...
25.05.24 - Boersia.de
Biogen Aktie: Sammelklage wegen Irreführung
Biogen, ein weltweit agierendes biopharmazeutisches Unternehmen, steht aktuell im Brennpunkt einer Sammelklage. Die Klage richtet sich gegen erfolgte Aktienkäufe des ...
23.05.24 - PR Newswire
BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! PR ...
23.05.24 - PR Newswire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Biogen Inc. with Losses to Contact the Firm
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Biogen Inc. with Losses to Contact the Firm PR Newswire

Newssuche

Videos

newspaper
13.06.24
Technical Trading: Zukauf-​Chance bei Top-Trade, wenn
Sugar No.11 Long Typ: Turbo Open End WKN: VV50DP Hebel: 5 Laufzeit: OpenEnd Einstieg: prozyklisch ... Mehr »